WOCKHARDT
|
WOCKHARDT Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -2.90 | -30.06 | -38.82 | -16.94 | 62.36 |
| CEPS(Rs) | 9.88 | -16.17 | -25.69 | -2.22 | -4.27 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 267.96 | 217.27 | 231.81 | 266.04 | 304.36 |
| Tax Rate(%) | -256.25 | -12.38 | 0.48 | 32.12 | 47.71 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 10.16 | 1.08 | 2.36 | 5.81 | -1.36 |
| EBIT Margin(%) | 6.15 | -3.19 | -7.54 | -2.18 | -6.88 |
| Pre Tax Margin(%) | -0.41 | -11.65 | -14.60 | -8.01 | -12.25 |
| PAT Margin (%) | -1.47 | -13.09 | -14.53 | -5.44 | -6.41 |
| Cash Profit Margin (%) | 4.14 | -6.91 | -8.66 | -0.62 | -1.10 |
| Performance Ratios | |||||
| ROA(%) | -0.78 | -6.67 | -8.42 | -3.71 | -3.93 |
| ROE(%) | -1.48 | -14.12 | -17.32 | -7.77 | -9.92 |
| ROCE(%) | 4.07 | -2.15 | -5.88 | -1.96 | -5.50 |
| Asset Turnover(x) | 0.53 | 0.51 | 0.58 | 0.68 | 0.61 |
| Sales/Fixed Asset(x) | 0.67 | 0.63 | 0.73 | 0.88 | 0.75 |
| Working Capital/Sales(x) | 9.16 | -5.02 | -2.81 | -6.73 | -5.52 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.49 | 1.58 | 1.37 | 1.14 | 1.33 |
| Receivable days | 60.36 | 71.63 | 73.25 | 65.29 | 85.04 |
| Inventory Days | 64.42 | 65.71 | 60.95 | 55.76 | 59.63 |
| Payable days | 218.94 | 255.81 | 293.71 | 232.91 | 255.87 |
| Valuation Parameters | |||||
| PER(x) | - | - | - | - | 6.12 |
| PCE(x) | 144.15 | -36.09 | -5.99 | -118.71 | -89.37 |
| Price/Book(x) | 5.31 | 2.69 | 0.66 | 0.99 | 1.36 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 8.21 | 3.78 | 1.50 | 1.63 | 2.44 |
| EV/Core EBITDA(x) | 54.36 | 86.64 | 17.85 | 16.52 | 95.62 |
| EV/EBIT(x) | 103.92 | -91.91 | -12.36 | -46.92 | -20.68 |
| EV/CE(x) | 3.98 | 1.93 | 0.76 | 0.69 | 0.89 |
| M Cap / Sales | 7.66 | 3.21 | 0.84 | 1.18 | 1.68 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 7.65 | 5.55 | -17.93 | 19.28 | -4.78 |
| Core EBITDA Growth(%) | 272.95 | -45.29 | -29.87 | 360.87 | -56.28 |
| EBIT Growth(%) | 306.96 | 64.29 | -187.50 | 64.89 | -381.15 |
| PAT Growth(%) | 87.92 | 23.99 | -122.58 | 6.06 | -115.30 |
| EPS Growth(%) | 90.35 | 22.55 | -129.10 | -127.17 | 1,097.71 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.43 | 0.63 | 0.57 | 0.49 | 0.70 |
| Current Ratio(x) | 1.21 | 0.74 | 0.56 | 0.76 | 0.73 |
| Quick Ratio(x) | 0.85 | 0.51 | 0.37 | 0.52 | 0.47 |
| Interest Cover(x) | 0.94 | -0.38 | -1.07 | -0.37 | -1.28 |
| Total Debt/Mcap(x) | 0.08 | 0.24 | 0.85 | 0.49 | 0.51 |
Compare Financial Ratios of peers of WOCKHARDT
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WOCKHARDT | ₹23,928.1 Cr | -6.7% | -13.2% | 70.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹380,702.0 Cr | -3.3% | -4.6% | -7.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,908.0 Cr | -9% | -13.6% | 24% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹120,896.0 Cr | -1.1% | 7% | 8.2% | Stock Analytics | |
| CIPLA | ₹119,988.0 Cr | -2% | 0.6% | -4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,122.0 Cr | -1.1% | -3.8% | -13.3% | Stock Analytics | |
WOCKHARDT Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WOCKHARDT | -6.7% |
-13.2% |
70.7% |
| SENSEX | -0.9% |
-4.4% |
1.6% |
You may also like the below Video Courses
